Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Hepatitis C virus (HCV)-related liver disease is the most common indication for liver
transplantation (LT). However, LT does not cure the infection, and therapeutic strategies
resulted in very limited efficacy and tolerability in LT recipients. In view of its
postulated safety profile, Silibinin seems an ideal drug to be used in the setting of HCV
recurrent patients after liver transplantation.